HealthDay News – Two genetic variants predicted the cardiovascular effect of intensive glycemic control in the ACCORD (Action to Control Cardiovascular Risk in Diabetes) trial, according to research published online August 15 in Diabetes Care.
Hetal S. Shah, MBBS, MPH, from the Joslin Diabetes Center in Boston, and colleagues analyzed 6.8 million common variants for genome-wide association with cardiovascular mortality among 2667 white patients from the ACCORD intensive treatment arm. In the entire ACCORD white genetic dataset (n=5360), significant loci were examined for their modulation of cardiovascular responses to the glycemic treatment assignment.
Researchers identified 2 loci that attained genome-wide significance as determinants of cardiovascular mortality in the ACCORD intensive arm (10q26 and 5q13). In the entire ACCORD white genetic dataset, a genetic risk score (GRS) defined by the 2 variants was a significant modulator of cardiovascular mortality response to treatment assignment.
Patients with a GRS of 0 had a reduction in cardiovascular mortality in response to intensive treatment (hazard ratio [HR]: 0.24; 95% confidence interval [CI]: 0.07-0.86); those with a GRS of 1 had no difference (HR: 0.92; 95% CI: 0.54-1.56); and those with a GRS ≥2 had an increase (HR: 3.08; 95% CI: 1.82-5.21).
“Further studies are warranted to determine whether these findings can be translated into new strategies to prevent cardiovascular complications of diabetes,” the authors wrote.
Disclosures: Several pharmaceutical companies provided study medications, equipment, or supplies.
Shah HS, Gao H, Morieri ML, et al. Genetic predictors of cardiovascular mortality during intensive glycemic control in type 2 diabetes: findings from the ACCORD clinical trial. Diabetes Care. 2016. doi:10.2337/dc16-0285.